Peltos Therapeutics (PTHS) Q1 2026: Zelsuvmi Prescriptions Jump 25% as PBM Access Doubles Units Dispensed

2026-05-14 | By EarningsIQ Research

Peltos Therapeutics delivered a robust Q1 2026, with Zelsuvmi prescription growth accelerating as expanded PBM access and sales force optimization fueled adoption across both dermatology and pediatrics. The company is leveraging its commercial infrastructure to prepare for two additional FDA-approved product launches, while maintaining disciplined cost control and balance sheet flexibility. Management’s focus on operational leverage and targeted expansion positions Peltos for continued share gains in a large, underpenetrated pediatric skin infection market.

Summary

• PBM Channel Drives Prescription Acceleration: Expanded payer access and sales force coverage are rapidly increasing Zelsuvmi adoption.
• Commercial Leverage Set for Zepi and Zeglize: Upcoming launches will utilize existing infrastructure, minimizing incremental cost.
• Repeat Prescriber Momentum: Depth and breadth of prescriber base continue to rise, supporting durable revenue growth.

Business Overview

Peltos Therapeutics develops and commercializes topical prescription therapies for infectious skin diseases, targeting both pediatric and adult patients. The company’s flagship product, Zelsuvmi, is the first FDA-approved at-home treatment for Molluscum contagiosum (MC), a common pediatric viral skin infection. Peltos generates revenue through direct sales to wholesalers and pharmacies, with commercial insurance and Medicaid coverage driving patient access. Its commercial platform is being leveraged to launch two additional FDA-approved products, Zepi (for impetigo) and Zeglize (for a complementary indication), both targeting similar prescriber bases and patient populations.

Performance Analysis

Peltos posted a 17% sequential increase in net product revenue, with Zelsuvmi prescriptions up 25% quarter-over-quarter, signaling strong demand and rapid market penetration in only the third full quarter since launch. The company’s expansion of its sales force from 50 to 64 representatives and a strategic PBM contract executed in late 2025 were key catalysts, with units dispensed within the PBM channel doubling and unique prescribers increasing by 121%. Importantly, inventory management remained disciplined, with minimal wholesaler inventory build and days on hand reduced by over a week, supporting the quality of reported revenue.

Gross-to-net (GTN) discounts remained favorable at 29.1%, though management anticipates a gradual move to the mid-30% range as payer contracting evolves. Operating expenses increased in line with commercial investments and launch preparation for Zepi and Zeglize, while the company’s recent $30 million term loan bolstered liquidity and working capital. Despite a reported net loss, Peltos improved its balance sheet and maintained flexibility for future commercialization activities.

• Prescription Growth Outpaces Expectations: Zelsuvmi’s 25% sequential prescription increase reflects both new and repeat prescriber gains, with April and early May data showing continued acceleration.
• Sales Force Expansion Delivers ROI: Newly added territories rapidly covered their costs, validating targeted commercial investment.
• Channel Access and Coverage Strengthen Adoption: 59% commercial and 99% Medicaid coverage rates, with PBM access streamlining patient onboarding and reducing prior authorization friction.

Peltos is executing on both breadth (new prescribers) and depth (repeat prescribing), laying a foundation for sustainable share gains as awareness and access build across both dermatology and pediatric channels.

Executive Commentary

Strategic Positioning

1. PBM and Payer Access as Growth Levers

Peltos’s December 2025 PBM contract has doubled units dispensed and sharply increased prescriber participation, reducing access friction and accelerating adoption. Medicaid coverage now reaches 99%, with most states waiving prior authorization, and commercial coverage at 59% continues to expand. This access infrastructure is foundational for both current and future product launches.

2. Commercial Infrastructure Optimization

The sales force expansion from 50 to 64 territory managers was highly targeted, with new territories rapidly driving prescription growth and covering their investment. Management is leveraging this infrastructure for upcoming Zepi and Zeglize launches, minimizing incremental cost and maximizing operational leverage.

3. Product Portfolio Synergy

Zepi (impetigo) and Zeglize (complementary indication) are both FDA-approved and address overlapping prescriber and patient populations, enabling efficient cross-selling and deeper market penetration. Both products are expected to launch in 2027, with manufacturing and inventory build underway, and will be detailed by the existing sales team.

4. Digital Engagement and HCP Education

Digital campaigns, including a Zelsuvmi YouTube commercial with 6.7 million views, have driven direct-to-patient and provider engagement, increasing awareness and driving new patient starts. Conference presence and educational content are further expanding the prescriber base, especially among pediatricians who have historically been less likely to treat MC.

5. Disciplined Capital Allocation

Peltos is maintaining a disciplined approach to SG&A and capital deployment, with commercial spend tightly linked to ROI and a focus on cost-effective, high-impact promotional channels. The recent $30 million term loan provides the runway needed for ongoing launches and platform expansion.

Key Considerations

This quarter demonstrated that Peltos’s commercial model is scaling efficiently, with prescription growth, payer access, and sales force ROI all exceeding launch-phase expectations. The company’s approach to coverage, channel management, and targeted expansion is positioning it to win share in a large, underpenetrated market, while upcoming launches will further leverage existing assets.

Key Considerations:

• Access Infrastructure as a Moat: PBM and Medicaid coverage have rapidly enabled broad patient access, a key barrier for competitors.
• Sales Force Productivity: New territories are generating prescriptions quickly, suggesting further expansion could be self-funding if needed.
• Repeat Prescriber Trends: Over 500 repeat prescribers in the most recent week, with both depth and breadth of prescriber base rising.
• Portfolio Expansion Strategy: Zepi and Zeglize launches are sequenced to maximize operational leverage, with no major sales force additions required.
• Gross-to-Net Management: GTN rates remain favorable but are expected to rise as payer contracting expands, impacting future net revenue realization.

Risks

Peltos faces execution risk around the timing and success of Zepi and Zeglize launches, as well as potential GTN headwinds if additional payer contracts are required or competitive pressures increase. There is also some uncertainty around the durability of prescription growth as the market matures, and the company remains exposed to regulatory, reimbursement, and operational risks as it scales. Management’s decision not to provide formal revenue guidance adds a degree of uncertainty for near-term modeling.

Forward Outlook

For Q2 2026, Peltos did not provide discrete revenue or earnings guidance, citing the early stage of the Zelsuvmi launch. Management reiterated:

• Confidence in continued prescription and revenue growth for Zelsuvmi, with April and early May data showing further acceleration.
• Launch timelines for Zepi (early 2027) and Zeglize (mid-2027) remain on track, with manufacturing and inventory build progressing as planned.

Management highlighted several factors that will drive performance:

• Continued expansion of prescriber base and repeat prescribing activity.
• Operational leverage from existing sales force as new products are launched.

Takeaways

Peltos’s Q1 2026 results confirm strong product-market fit for Zelsuvmi and validate its commercial strategy, while setting the stage for multi-product leverage and operational efficiency in a large, under-treated pediatric skin infection market.

• Prescription Acceleration: PBM access and sales force expansion are driving both new and repeat prescriber growth, with downstream revenue implications as awareness and coverage expand.
• Platform Leverage: Upcoming Zepi and Zeglize launches will be layered onto the current infrastructure, supporting margin improvement and risk mitigation.
• Watch for GTN and Payer Dynamics: Investors should monitor the evolution of gross-to-net rates and payer mix, as these will impact net revenue realization and long-term profitability.

Conclusion

Peltos Therapeutics delivered a quarter of accelerating prescription growth and commercial execution, with Zelsuvmi’s at-home, first-line positioning resonating across prescriber segments. The company’s disciplined approach to sales force expansion, payer access, and portfolio leverage positions it for continued share gains and operational efficiency as it prepares for two additional product launches in 2027.

Industry Read-Through

Peltos’s rapid acceleration in at-home prescription therapy adoption highlights a broader shift in pediatric and dermatology markets toward convenient, parent-administered treatments with strong payer coverage. The company’s success in quickly scaling PBM and Medicaid access demonstrates the critical importance of channel and reimbursement infrastructure for new specialty launches. Competitors in pediatric infectious disease and dermatology will need to prioritize payer contracting and digital engagement strategies to match Peltos’s momentum. The operational leverage achieved through targeted sales force deployment and multi-product detailing offers a model for other specialty pharma companies seeking to maximize ROI on commercial investments, especially in large, underpenetrated markets.

PTHS Healthcare Pharmaceuticals Payer Access Pediatrics Dermatology Commercialization Prescription Growth